Case Report Management of Refractory Gout with Tumor Necrosis Factor Inhibitor and Febuxostat
Management of Refractory Gout with Tumor Necrosis Factor Inhibitor and Febuxostat
Keywords:
Chronic rheumatic disease, Tumor necrosis factor, Refractory goutAbstract
Gouty arthritis is a metabolic disorder associated with hyperuricemia and despite the availability of various pharmacotherapeutic
agents, such as uricosuric, uric acid synthesis inhibitors, NSAIDs, corticosteroids and biologics – a new addition, some
hyperuricemia patients are drug refractory. Refractory gout remains a persistent challenge for diagnosis and management for
clinicians. We present a case of chronic gouty arthropathy was successfully treated by combining two different group of drugs
such as xanthine oxidase inhibitor Febuxostat and TNF antagonists Etanercept.
References
Fargetti S, Goldenstein-Schainberg C, Abreu AS, Fuller R.
Refractory gout attack. Case Rep Med 2012;2012:657694.
Han X, Yin Y, Cao Y, Chu X, Han Y, Di H, et al. Rheumatologists’
understanding of refractory gout: A questionnaire survey in
China. J Int Med Res 2021;49:1-10.
Zhang Y, Pan R, Xu Y, Zhao Y. Treatment of refractory gout
with TNF-α antagonist etanercept combined with febuxostat.
Ann Palliat Med 2020;9:4332-8.
Lange U, Schumann C, Schmidt KL. Current aspects of
uses. Eur J Med Res 2001;6:150-60.
Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy
for acute gout: A clinical trial and review of the literature.
Semin Arthritis Rheum 1990;19:329-36.
Moreland LW, Schiff MH, Baumgartner SW, Tindall EA,
Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in
rheumatoid arthritis. A randomized, controlled trial. Ann Intern
Med 1999;130:478-86.
Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis:
Pathophysiology and treatment with TNF inhibitors. Ann
Rheum Dis 2002;61:298-304.
Lamprecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M,
Gross WL, et al. Effectiveness of TNF-alpha blockade
with infliximab in refractory Wegener’s granulomatosis.
Rheumatology (Oxford) 2022;41:1303-7.
Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P
Le Hello C, et al. Efficacy of the anti-TNF-alpha antibody
infliximab against refractory systemic vasculitides: An
open pilot study on 10 patients. Rheumatology (Oxford)
;41:1126-32.
Tausche AK, Richter K, Grässler A, Hänsel S, Roch B,
Schröder HE. Severe gouty arthritis refractory to antiinflammatory
drugs: Treatment with anti-tumour necrosis
factor alpha as a new therapeutic option. Ann Rheum Dis
;63:1351-2.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Journal of Bones & Muscles Health
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
